

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**SECTION 1. IDENTIFICATION**

Product name : TAMIFLU Powder for Susp. 30 mg/5ml

Product code : RO064-0796/V36-04

Common name(s),
synonym(s) of the substance : TAMIFLU DRY SYRUP**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone
In case of emergencies: : US CHEMTREC PHONE (800)-424-9300**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)****Hazards for the product as supplied**

Combustible dust

Skin sensitization : Category 1

Carcinogenicity : Category 2

Other hazards

None known.

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : May form combustible dust concentrations in air.
H317 May cause an allergic skin reaction.
H351 Suspected of causing cancer.

TAMIFLU Powder for Susp. 30 mg/5ml
Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

Precautionary Statements

: **Prevention:**

P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read and understood.
 P261 Avoid breathing dust.
 P272 Contaminated work clothing must not be allowed out of the workplace.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.
 P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
 P363 Wash contaminated clothing before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS No./Unique ID | Concentration (% w/w) | Trade secret |
|--|-------------------|-----------------------|--------------|
| D-Glucitol | 50-70-4* | 86 | - |
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, sodium salt (1:1) | 18996-35-5* | 5.5 | - |
| Oseltamivir phosphate | 204255-11-8* | 3.9 | - |
| Titanium oxide (TiO2) | 13463-67-7* | 1.5 | - |
| Xanthan gum | 11138-66-2* | 1.5 | - |
| non hazardous compounds | - | 1.34 | - |
| Benzoic acid, sodium salt (1:1) | 532-32-1* | 0.25 | - |
| 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, sodium salt (1:1) | 128-44-9* | 0.01 | - |

* Indicates that the identifier is a CAS No.

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**SECTION 4. FIRST AID MEASURES**

General advice : Move out of dangerous area.
Show this material safety data sheet to the doctor in attendance.
Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact : If on skin, rinse well with water.

In case of eye contact : Flush eyes with water as a precaution.
Remove contact lenses.
Protect unharmed eye.
Keep eye wide open while rinsing.
If eye irritation persists, consult a specialist.

If swallowed : Induce vomiting immediately and call a physician.
Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Take victim immediately to hospital.

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.
Suspected of causing cancer.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Carbon oxides
Sodium oxides
Nitrogen oxides (NOx)

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

Oxides of phosphorus

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Avoid dust formation.
Avoid breathing dust.
Ensure adequate ventilation.
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Prevent product from entering drains.
Prevent further leakage or spillage if safe to do so.
If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Avoid dust formation.
Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : Avoid formation of respirable particles.
Do not breathe vapors/dust.
Avoid exposure - obtain special instructions before use.
Avoid contact with skin and eyes.
For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.
Provide sufficient air exchange and/or exhaust in work rooms.
Dispose of rinse water in accordance with local and national regulations.
Persons susceptible to skin sensitization problems or asthma, allergies, chronic or recurrent respiratory disease should not be employed in any process in which this mixture is being used.

Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.
Electrical installations / working materials must comply with the technological safety standards.

TAMIFLU Powder for Susp. 30 mg/5ml
Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

Storage temperature : Protect from heat and light
Protect from moisture.

Further information on storage stability : Keep in a dry place.
No decomposition if stored and applied as directed.

Packaging material : Suitable material: glass, Stainless steel

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|------------------------------------|-------------|-------------------------------------|---|---|
| Oseltamivir phosphate | 204255-11-8 | IOEL | 0.2 mg/m ³ | Roche Industrial Hygiene Committee (RIHC) |
| Titanium oxide (TiO ₂) | 13463-67-7 | TWA (total dust) | 15 mg/m ³ | OSHA Z-1 |
| | | TWA (Total dust) | 10 mg/m ³ | OSHA P0 |
| | | TWA (Respirable particulate matter) | 0.2 mg/m ³ (Titanium dioxide) | ACGIH |
| | | TWA (Respirable particulate matter) | 2.5 mg/m ³ (Titanium dioxide) | ACGIH |

Predicted No Effect Concentration (PNEC):

| Substance name | Environmental Compartment | Value |
|-------------------------------|---------------------------|----------|
| Oseltamivir phosphate | Surface waters | 100 µg/l |
| Remarks:Based on chronic data | | |

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Hand protection**

Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of contact through splashing:

Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Eye wash bottle with pure water
Tightly fitting safety goggles

Skin and body protection : Dust impervious protective suit
Choose body protection according to the amount and
concentration of the dangerous substance at the work place.

Hygiene measures : When using do not eat or drink.
When using do not smoke.
Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white, light yellow

Odor : odorless

Odor Threshold : Not applicable

pH : 3.0 - 5.0 (68 °F / 20 °C)
suspension

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Self-ignition : No data available

Upper explosion limit / Upper : No data available

TAMIFLU Powder for Susp. 30 mg/5ml

Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

flammability limit

Lower explosion limit / Lower
flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Solubility in other solvents : No data available

Partition coefficient: n-
octanol/water : log Pow: 0.36
pH: 7.4
The value is given in analogy to the following substances:
Oseltamivir phosphate

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : Not applicable

Viscosity, kinematic : Not applicable

Explosive properties : No data available

Oxidizing properties : No data available

Particle characteristics

Particle Size Distribution : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Possibility of hazardous
reactions : No decomposition if stored and applied as directed.
Dust may form explosive mixture in air.

Conditions to avoid : No data available

Incompatible materials : Not applicable

Hazardous decomposition
products : No hazardous decomposition products are known.

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified due to lack of data.

Product:

Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:**Oseltamivir phosphate:**

Acute oral toxicity : MNLD (Maximum No Lethal Dose) (Rat): > 2,000 mg/kg
Assessment: The component/mixture is minimally toxic after single ingestion.

Titanium oxide (TiO2):

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 425

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Skin corrosion/irritation

Not classified due to lack of data.

Product:

Remarks : May cause skin irritation and/or dermatitis.

Components:**Titanium oxide (TiO2):**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Not classified due to lack of data.

Product:

Remarks : Product dust may be irritating to eyes, skin and respiratory system.

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Components:****Oseltamivir phosphate:**

| | | |
|---------|---|------------------------------------|
| Species | : | Rabbit |
| Result | : | Eye irritation |
| Method | : | OECD Test Guideline 405 |
| GLP | : | yes |
| Remarks | : | May cause irreversible eye damage. |

Titanium oxide (TiO2):

| | | |
|---------|---|-------------------------|
| Species | : | Rabbit |
| Result | : | No eye irritation |
| Method | : | OECD Test Guideline 405 |

Respiratory or skin sensitization**Skin sensitization**

May cause an allergic skin reaction.

Respiratory sensitization

Not classified due to lack of data.

Product:

| | | |
|---------|---|-----------------------|
| Remarks | : | Causes sensitization. |
|---------|---|-----------------------|

Components:**Oseltamivir phosphate:**

| | | |
|------------|---|--|
| Species | : | Guinea pig |
| Assessment | : | May cause sensitization by skin contact. |
| Method | : | OECD Test Guideline 406 |
| GLP | : | yes |

Titanium oxide (TiO2):

| | | |
|------------|---|------------------------------------|
| Species | : | Guinea pig |
| Assessment | : | Does not cause skin sensitization. |
| Method | : | OECD Test Guideline 406 |

Germ cell mutagenicity

Not classified due to lack of data.

Components:**Oseltamivir phosphate:**

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Result: negative |
| | | Remarks: In vitro tests did not show mutagenic effects |

Carcinogenicity

Suspected of causing cancer.

Components:**Titanium oxide (TiO2):**

| | | |
|-------------------|---|--|
| Carcinogenicity - | : | Limited evidence of a carcinogenic effect. |
|-------------------|---|--|

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Assessment**

| | | |
|-------------|--|------------|
| IARC | Group 2B: Possibly carcinogenic to humans Titanium oxide (TiO ₂) | 13463-67-7 |
| OSHA | No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens. | |
| NTP | No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. | |

Reproductive toxicity

Not classified due to lack of data.

Components:**Oseltamivir phosphate:**

| | | |
|------------------------------|---|---|
| Effects on fertility | : | Species: laboratory animal Result: Animal testing did not show any effects on fertility. |
| Effects on fetal development | : | Species: laboratory animal Result: No teratogenic effects. |

STOT-single exposure

Not classified due to lack of data.

Components:**Oseltamivir phosphate:**

| | | |
|------------|---|--|
| Assessment | : | The substance or mixture is not classified as specific target organ toxicant, single exposure. |
|------------|---|--|

STOT-repeated exposure

Not classified due to lack of data.

Components:**Oseltamivir phosphate:**

| | | |
|------------|---|--|
| Assessment | : | The substance or mixture is not classified as specific target organ toxicant, repeated exposure. |
|------------|---|--|

Repeated dose toxicity**Components:****Oseltamivir phosphate:**

| | | |
|-------------------|---|---------------------|
| Species | : | Rat |
| NOAEL | : | 250 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 4 Weeks |
| GLP | : | yes |
| Remarks | : | Subchronic toxicity |

TAMIFLU Powder for Susp. 30 mg/5ml

Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Aspiration toxicity**

Not classified due to lack of data.

Components:**Oseltamivir phosphate:**

No data available

Further information**Product:**

Remarks : No data available

Components:**Oseltamivir phosphate:**

Remarks : Not phototoxic (in vitro)

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Oseltamivir phosphate:**Toxicity to fish : LC50 (Cyprinus carpio (Carp)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 33 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202Toxicity to algae/aquatic plants : ErC50 (Selenastrum capricornutum (green algae)): 463 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201EyC50 (Selenastrum capricornutum (green algae)): 59 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201NOErC (Selenastrum capricornutum (green algae)): 46 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201NOEyC (Selenastrum capricornutum (green algae)): 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201Toxicity to microorganisms : (activated sludge): 30 mg/l
Exposure time: 14 d
Method: OECD Test Guideline 302C
GLP: no
Remarks: no adverse influence on substrate biodegradation

TAMIFLU Powder for Susp. 30 mg/5ml

Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Titanium oxide (TiO2):**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l
Exposure time: 96 h
Test Type: static test

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10,000 mg/l
Exposure time: 96 h
Test Type: semi-static test
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : LC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 48 h
Test Type: static test
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Test Type: static test
Method: OECD Test Guideline 201

EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h
Method: ISO 10253

NOEC (Skeletonema costatum (marine diatom)): 5,600 mg/l
Exposure time: 72 h
Method: ISO 10253

Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Persistence and degradability**Components:****Oseltamivir phosphate:**

Biodegradability : Biodegradation: 3.0 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Biodegradation: 2.8 %
Exposure time: 14 d
Method: OECD Test Guideline 301B

Titanium oxide (TiO2):

Biodegradability : Remarks: Not applicable

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Bioaccumulative potential****Components:****Oseltamivir phosphate:**Partition coefficient: n-octanol/water : log Pow: 0.36
pH: 7.4**Titanium oxide (TiO2):**

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects**Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**Waste from residues : Do not dispose of waste into sewer.
Do not contaminate ponds, waterways or ditches with chemical or used container.
Send to a licensed waste management company.
Contaminated packaging : Empty remaining contents.
Dispose of as unused product.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**IMDG-Code**

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

No data available

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Respiratory or skin sensitization
Carcinogenicity

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

TAMIFLU Powder for Susp. 30 mg/5ml
Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025**Clean Water Act**

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

| | |
|--|------------|
| Titanium oxide (TiO ₂) | 13463-67-7 |
| 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, sodium salt (1:1) | 128-44-9 |

Pennsylvania Right To Know

| | |
|--|-------------|
| D-Glucitol | 50-70-4 |
| 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, sodium salt (1:1) | 18996-35-5 |
| Oseltamivir phosphate | 204255-11-8 |
| Titanium oxide (TiO ₂) | 13463-67-7 |
| 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, sodium salt (1:1) | 128-44-9 |

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium oxide (TiO₂), which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

| | |
|------------------------------------|------------|
| Titanium oxide (TiO ₂) | 13463-67-7 |
|------------------------------------|------------|

The ingredients of this product are reported in the following inventories:

| | |
|-------|---|
| AIIC | : Not in compliance with the inventory |
| DSL | : This product contains the following components that are not on the Canadian DSL nor NDSL. |
| | Oseltamivir phosphate |
| | non hazardous compounds |
| NZIoC | : Not in compliance with the inventory |
| ENCS | : Not in compliance with the inventory |
| ISHL | : Not in compliance with the inventory |
| KECI | : Not in compliance with the inventory |


TAMIFLU Powder for Susp. 30 mg/5ml
Version
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

| | | |
|-------|---|---|
| PICCS | : | Not in compliance with the inventory |
| IECSC | : | Not in compliance with the inventory |
| TCSI | : | Not in compliance with the inventory |
| TSCA | : | Product contains substance(s) not listed on TSCA inventory. |
| TECI | : | Not in compliance with the inventory |

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION**Further information****NFPA 704:****HMIS® IV:**

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

| | | |
|----------------|---|--|
| ACGIH | : | USA. ACGIH Threshold Limit Values (TLV) |
| OSHA P0 | : | USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values) |
| OSHA Z-1 | : | USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants |
| ACGIH / TWA | : | 8-hour, time-weighted average |
| OSHA P0 / TWA | : | 8-hour time weighted average |
| OSHA Z-1 / TWA | : | 8-hour time weighted average |

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response,

TAMIFLU Powder for Susp. 30 mg/5mlVersion
1.1Revision Date:
11/05/2025Date of last issue: 06/14/2025
Date of first issue: 06/14/2025

Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 11/05/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2504